Darunavir + ritonavir (DRV/r) should be considered in future World Health Organization guidelines

Based on a systematic review, Darunavir with ritonavir (DRV/r) outperformed ritonavir-boosted lopinavir at 48 weeks, 96 weeks, and 192 weeks. DRV/r was similar to dolutegravir at 48 weeks but less effective at 96 weeks. Initial antiretroviral therapy regimens for HIV using DRV/r should be considered in future World Health Organization guidelines. (G. Rutherford, CAPS/PRC affiliate)

Read more here.